Hyperparathyroidism in Chronic Kidney Disease: Complexities Within the Commonplace

Overview

Journal Clin Med (Lond)

Specialty General Medicine

Date 2012 Aug 31

PMID 22930877

Citations 1

Authors

Michael M Cai

Lawrence P McMahon

Edward R Smith

David S Williams

Stephen G Holt

Affiliations

Soon will be listed here.

Abstract

Secondary hyperparathyroidism in patients with chronic kidney disease (CKD) is common and usually caused by associated metabolic abnormalities, in particular, hypocalcaemia and hyperphosphataemia. Nevertheless, other causes of hyperparathyroidism can exist concurrently with CKD, challenging diagnostic interpretation and therapeutic intervention. We present four cases of hyperparathyroidism in patients with CKD that highlight some of these dilemmas.

Citing Articles

Single-cell RNA sequencing reveals the role of cell heterogeneity in the sex difference in primary hyperparathyroidism.

Lu S, Chen X, Gong M, Chen S, Zhang J, Zhang X Front Endocrinol (Lausanne). 2023; 14:1165890.

PMID: 36960393 PMC: 10028180. DOI: 10.3389/fendo.2023.1165890.

References

Seikrit C, Muhlfeld A, Groene H, Floege J . Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic. Nat Rev Nephrol. 2010; 7(4):237-41. DOI: 10.1038/nrneph.2010.169. View

Pollak M, Brown E, Chou Y, Hebert S, Marx S, Steinmann B . Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993; 75(7):1297-303. DOI: 10.1016/0092-8674(93)90617-y. View

Jayasena C, Mahmud M, Palazzo F, Donaldson M, Meeran K, Dhillo W . Utility of the urine calcium-to-creatinine ratio to diagnose primary hyperparathyroidism in asymptomatic hypercalcaemic patients with vitamin D deficiency. Ann Clin Biochem. 2011; 48(Pt 2):126-9. DOI: 10.1258/acb.2010.010202. View

Meola M, Petrucci I, Colombini E, Barsotti G . Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2011; 58(3):485-91. DOI: 10.1053/j.ajkd.2011.03.030. View

Smith E, Ford M, Tomlinson L, Weaving G, Rocks B, Rajkumar C . Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta. 2011; 412(11-12):1008-11. DOI: 10.1016/j.cca.2011.02.009. View

Johnson N, Carty S, Tublin M . Parathyroid imaging. Radiol Clin North Am. 2011; 49(3):489-509, vi. DOI: 10.1016/j.rcl.2011.02.009. View

Hebert S . Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int. 1996; 50(6):2129-39. DOI: 10.1038/ki.1996.539. View

Gardham C, Stevens P, Delaney M, LeRoux M, Coleman A, Lamb E . Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol. 2010; 5(7):1261-7. PMC: 2893062. DOI: 10.2215/CJN.09471209. View

. Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int. 2016; 76113:S50-99. DOI: 10.1038/ki.2009.192. View

10.

Lumachi F, Ermani M, Basso S, Zucchetta P, Borsato N, Favia G . Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. Endocr Relat Cancer. 2001; 8(1):63-9. DOI: 10.1677/erc.0.0080063. View

11.

Lai E, Ching A, Leong H . Secondary and tertiary hyperparathyroidism: role of preoperative localization. ANZ J Surg. 2007; 77(10):880-2. DOI: 10.1111/j.1445-2197.2007.04264.x. View

12.

Bilezikian J, Khan A, Potts Jr J . Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94(2):335-9. PMC: 3214274. DOI: 10.1210/jc.2008-1763. View

13.

Peacock M, Bilezikian J, Bolognese M, Borofsky M, Scumpia S, Sterling L . Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2010; 96(1):E9-18. PMC: 3203649. DOI: 10.1210/jc.2010-1221. View

14.

Wolf M . Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens. 2009; 18(6):463-8. DOI: 10.1097/MNH.0b013e328331a8c8. View

15.

Chonchol M, Locatelli F, Abboud H, Charytan C, de Francisco A, Jolly S . A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2008; 53(2):197-207. DOI: 10.1053/j.ajkd.2008.09.021. View

16.

. Chapter 3.1: Diagnosis of CKD-MBD: biochemical abnormalities. Kidney Int. 2016; 76113:S22-49. DOI: 10.1038/ki.2009.191. View

17.

Numerow L, Morita E, Clark O, Higgins C . Persistent/recurrent hyperparathyroidism: a comparison of sestamibi scintigraphy, MRI, and ultrasonography. J Magn Reson Imaging. 1995; 5(6):702-8. DOI: 10.1002/jmri.1880050614. View

18.

Yamashita H, Noguchi S, Uchino S, Watanabe S, Murakami T, Ogawa T . Influence of renal function on clinico-pathological features of primary hyperparathyroidism. Eur J Endocrinol. 2003; 148(6):597-602. DOI: 10.1530/eje.0.1480597. View

19.

Levi M, Ellis M, Berl T . Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest. 1983; 71(6):1624-32. PMC: 370368. DOI: 10.1172/jci110918. View

20.

Copley J, Wuthrich R . Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2010; 25(1):24-39. DOI: 10.1111/j.1399-0012.2010.01287.x. View